indazoles has been researched along with Angiogenesis, Pathologic in 94 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (24.47) | 29.6817 |
| 2010's | 67 (71.28) | 24.3611 |
| 2020's | 4 (4.26) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, HY; Fu, LS; Li, MM; Liu, M; Liu, X; Liu, Z; Ma, YY; Sun, HT; Tian, XY; Wang, Y; Wang, YF; Zhang, PC | 1 |
| Banerjee, S; Clamp, AR; Dive, C; Hall, M; Hasan, J; Jayson, GC; Lyon, AR; Morgan, RD; Orbegoso, C; Rustin, GJS; Taylor, S; Tugwood, J; Zhou, C | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Higuchi, T; Hoffman, RM; Kanaya, F; Miyake, K; Nishida, K; Oshiro, H; Sugisawa, N; Tome, Y | 1 |
| Li, C; Pan, X; Shan, Y; Si, R; Sun, Y; Wang, B; Zhang, J | 1 |
| Chellappan, DK; Chellian, J; Foo, JH; Gupta, G; Hang, LY; Ling, J; Nathan, S; Ng, ZY; Sim, YJ; Singh, Y; Theng, CW; Wong, M; Yang, GJ | 1 |
| De Meyer, GRY; Martinet, W; Van der Veken, B | 1 |
| Bertozzi, CR; Brewer, WJ; Cambier, CJ; Cronan, MR; Foglia, MD; Marass, M; Poss, KD; Rossi, A; Stainier, DYR; Tobin, DM; Walton, EM | 1 |
| Chen, S; Gong, P; Huang, C; Lowerison, MR; Lucien, F; Song, P; Wang, D | 1 |
| Waxman, DJ; Zhang, K | 1 |
| Chang, LH; Lai, CY; Pan, SL; Teng, CM; Tsai, AC | 1 |
| Bozzi, F; Casali, PG; Cominetti, D; Gronchi, A; Libertini, M; Messina, A; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Stacchiotti, S; Tamborini, E; Tortoreto, M; Zaffaroni, N | 1 |
| Erlichman, C; Flynn, PJ; Ho, WM; Miles, KM; Millward, M; Picus, J; Pili, R; Pitot, H; Qin, R; Tan, W; Vaishampayan, U | 1 |
| Goh, V; Gore, M; Juttla, JK; Larkin, JM; Nathan, PD; Reynolds, AR; Thompson, VL; Vasudev, NS | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Groppi, VE; McEwen, DP; O'Clair, B; Wolfe, A | 1 |
| Cai, P; Chen, W; Fang, X; Gao, Z; Gu, Y; Shu, Y; Sun, Y; Tao, F; Xu, Q; Yuan, H; Zhang, X | 1 |
| Brown, NJ; Reed, MW; Staton, CA; Woll, PJ; Young, RJ | 1 |
| Evans, CE; Grover, SP; Humphries, J; Lyons, OT; Modarai, B; Patel, AP; Patel, AS; Saha, P; Smith, A; Waltham, M | 1 |
| Chen, S; Cohen-Sola, KA; Goydos, JS; Jeong, BS; Koo, J; Li, J; Lin, Y; Mehnert, JM; Shin, SS; Wen, Y | 1 |
| Colecchia, M; De Braud, F; Garanzini, E; Grassi, P; Iacovelli, R; Procopio, G; Testa, I; Torelli, T; Verzoni, E | 1 |
| Furukawa, H; Furuse, J; Ojima, H; Shibata, T; Shimizu, H; Takahashi, H | 1 |
| Cheng, J; Fuks, Z; Haimovitz-Friedman, A; Kolesnick, RN; Powell, SN; Rao, SS; Thompson, C | 1 |
| Lu, L; Martuza, RL; Rabkin, SD; Saha, D; Wakimoto, H | 1 |
| Chernova, M; Gao, L; Jia, W; Mihm, MC; Nadora, DM; Nelson, JS; Phan, S; Preciado, SM; Sun, V; Tan, W; Wang, G | 1 |
| Han, Y; Li, P; Song, K; Xie, Z; Xu, X; Zhang, L; Zhao, Y; Zhou, L; Zhou, P | 1 |
| Araujo, D; Fu, S; Hess, K; Hong, D; Hou, MM; Hwu, P; Janku, F; Karp, D; Kee, B; Kurzrock, R; Meric-Bernstam, F; Naing, A; Piha-Paul, S; Subbiah, V; Tsimberidou, A; Wheler, J; Wolff, R; Zinner, R | 1 |
| Berndsen, RH; Bonvin, D; Dyson, PJ; Griffioen, AW; Nowak-Sliwinska, P; Scherrer, E; Weiss, A; Wong, TJ | 1 |
| Aversa, C; Geuna, E; Leone, F; Martinello, R; Milani, A; Montemurro, F; Serini, G; Valdembri, D; Zucchini, G | 1 |
| Guo, XL; Li, WB; Lu, YY; Wang, JJ; Zhang, XK | 1 |
| Cogle, CR; Drusbosky, L; Gars, E; McGee, C; Meacham, A; Scott, EW; Trujillo, A; Wise, E | 1 |
| Banerjee, S; McLachlan, J | 1 |
| Ceelen, W; De Wever, O; Descamps, B; Gremonprez, F; Izmer, A; Vanhaecke, F; Vanhove, C | 1 |
| Collet, G; Dulak, J; Jozkowicz, A; Kieda, C; Kloska, D; Szade, A; Szade, K; Zukowska, M | 1 |
| Kim, D; Kwon, A; Lee, BY; Min, KH; Nguyen, HK; Song, J; Suh, W; Yoo, J | 1 |
| Crawford, K; Dusing, M; Frischer, JS; Knod, JL | 1 |
| Bocci, G; Di Desidero, T; Kerbel, RS; Man, S; Xu, P | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
| Afshar-Kharghan, V; Armaiz-Pena, GN; Bottsford-Miller, J; Burns, AR; Cho, MS; Choi, HJ; Dalton, HJ; Gharpure, KM; Gutschner, T; Haemmerle, M; Han, HD; Hansen, JM; Lopez-Berestein, G; Mangala, LS; Nagaraja, AS; Nick, AM; Pecot, CV; Pradeep, S; Rupaimoole, R; Sood, AK; Stone, RL; Taylor, ML; Wu, SY; Zand, B | 1 |
| Mukherji, M; Subhani, S; Vavilala, DT | 1 |
| Andrikou, K; Bianconi, M; Bittoni, A; Burattini, L; Cascinu, S; Del Prete, M; Faloppi, L; Giampieri, R; Loretelli, C; Montironi, R; Scartozzi, M; Zizzi, A | 1 |
| Alimzhanov, M; Alsop, DC; Atkins, MB; Bhasin, MK; Bhatt, RS; Callea, M; Khanna, P; Kumar, R; Mier, JW; Pearsall, RS; Signoretti, S; Solban, N; Song, J; Wang, X | 1 |
| Bieche, I; Bousquet, G; Bryan, BA; de Gramont, A; Dos Santos, C; Faivre, S; Gapihan, G; Janin, A; Lopez, A; Martinet, M; Mitchell, DC; Neuzillet, C; Raymond, E; Riveiro, ME; Serova, M; Tijeras-Raballand, A | 1 |
| Bandara, NA; Bates, CD; Hoylman, EK; Low, PS; Lu, Y | 1 |
| Albert, DH; Chen, CS; Davidsen, SK; Glaser, KB; Jasinghe, VJ; Khng, J; Poon, LF; Senthilnathan, P; Xie, Z; Zhou, J | 1 |
| Amundson, K; Bender, SL; Chen, JH; Grazzini, ML; Hallin, ME; Hu-Lowe, DD; Kania, RS; McTigue, MA; Murray, BW; O'Connor, P; Rewolinski, DA; Shalinsky, DR; Wickman, GR; Wu, EY; Yamazaki, S; Zou, HY | 1 |
| Gee, J; Harrison, MR; Huang, W; Liu, G | 1 |
| Kelly, RJ; Rixe, O | 1 |
| Al-Halafi, A; Al-Mohanna, FA; Al-Mohanna, FH; Alsmadi, O; DeNiro, M | 1 |
| Abrey, LE; Butowski, NA; Chang, SM; Deangelis, LM; Fine, HA; Iwamoto, FM; Lamborn, KR; Mehta, MP; Prados, MD; Robins, HI; Zhang, WT | 1 |
| Altorki, N; Bordogna, W; Heymach, JV; Nikolinakos, PG; Ottesen, LH; Rajagopalan, D; Tran, HT; Yan, S; Yankelevitz, D | 1 |
| Chang, YL; Guh, JH; Kuo, SC; Lee, FY; Pai, HC; Pan, SL; Peng, CY; Teng, CM; Tsai, AC | 1 |
| Carroll, AR; Coleman, RL; Dumble, M; Jennings, N; Kamat, AA; Kumar, R; Lin, YG; Lu, C; Matsuo, K; Merritt, WM; Nick, AM; Shahzad, MM; Sood, AK; Spannuth, WA; Stone, RL; Zhang, S | 1 |
| Cruz-Munoz, W; Hashimoto, K; Kerbel, RS; Kumar, R; Man, S; Tang, T; Xu, P | 1 |
| Deville, JL; Duffaud, F; Huynh, T; Salas, S | 1 |
| Betof, AS; Dewhirst, MW; Dreher, MR; Hanna, G; Nixon, AB; Spasojevic, I; Tailor, TD; Yarmolenko, PS | 1 |
| Bourredjem, A; Daudigeos-Dubus, E; Farace, F; Geoerger, B; Monnet, Y; Opolon, P; Rössler, J; Vassal, G | 1 |
| Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R | 1 |
| Cao, W; Du, K; Duan, Y; Hu, Y; Huang, H; Lai, X; Lin, J; Liu, L; Wang, Y; Wu, K; Xiao, H; Yu, Q; Zhang, L | 1 |
| Alì, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Di Paolo, A; Fioravanti, A; Fontanini, G; Orlandi, P | 1 |
| Goh, BC; Hartono, S; Humerickhouse, RA; Koh, TS; Low, AS; Ong, AB; Rumpel, H; Soo, RA; Sukri, N; Tai, BC; Thng, CH; Wong, CI | 1 |
| Blute, T; Chen, CS; Ma, J; Waxman, DJ | 1 |
| Maráz, A | 1 |
| Albert, DH; Davidsen, SK; Fox, GB; Jiang, F; Lesniewski, R; Luo, Y; McKeegan, EM; Tapang, P; Zhang, K | 1 |
| Eichler, W; King, AG; Lange, J; Niemeyer, M; Nishiwaki, A; Wiedemann, P; Yafai, Y; Yang, XM; Yasukawa, T | 1 |
| Chowbay, B; Gao, F; Goh, BC; Ivy, P; Koh, TS; Leong, SS; Lim, WT; Ng, QS; Singh, O; Tan, DS; Tan, EH; Thng, CH; Toh, CK | 1 |
| Baruchel, S; Kerbel, RS; Kumar, S; Man, S; Mokhtari, RB; Oliveira, ID; Sheikh, R; Wu, B; Xu, P; Yeger, H; Zhang, L | 1 |
| Anwar, T; Bernardo, M; Choyke, P; Gril, B; Ileva, L; Liewehr, DJ; Palmieri, D; Qian, Y; Steeg, PS; Steinberg, SM | 1 |
| Bernhard, EJ; Im, J; McKenna, WG; Muschel, RJ; Qayum, N; Stratford, MR | 1 |
| Albert, DH; Chakravartty, A; Cole, TB; Cox, BF; Davidsen, SK; Fox, GB; Hradil, VP; Jiang, F; Luo, Y; McKeegan, EM; Reuter, D | 1 |
| Döme, B; Török, S | 1 |
| Dong, S; Ke, S; Kong, J; Li, X; Pan, B; Sun, WB; Zheng, L; Zhou, A | 1 |
| Bagnoli, P; Dal Monte, M; Landi, D; Martini, D | 1 |
| Manley, E; Waxman, DJ | 1 |
| Donehower, RC; Pili, R | 1 |
| Cho, YS; Chun, YS; Kim, J; Kim, MS; Lee, JC; Park, JW; Yeo, EJ | 1 |
| Chang, JH; Chang, YL; Cheng, FC; Guh, JH; Kuo, SC; Lee, FY; Pan, SL; Peng, CY; Teng, CM; Wang, SW | 1 |
| Collins, JM | 1 |
| Freddo, JL; Herbst, RS; Kies, MS; Liu, G; Park, JW; Pithavala, YK; Reich, SD; Rugo, HS; Steinfeldt, HM; Wilding, G | 1 |
| Garber, K | 1 |
| Brasch, RC; Fu, YJ; Henry, RG; Hu-Lowe, DD; Hylton, NM; Li, KL; McShane, TM; Pallavicini, MG; Park, JW; Shalinsky, DR; Wilmes, LJ | 1 |
| Chang, YL; Guh, JH; Huang, DM; Kuo, SC; Lee, FY; Lin, CH; Liu, YN; Pai, HC; Pan, SL; Peng, CY; Teng, CM | 1 |
| Bogdanov, AA; Figueiredo, J; Hu-Lowe, D; Kang, HW; Kim, YR; Mahmood, U; Petrovsky, A; Reichardt, W; Torres, D; Weissleder, R; Yudina, A | 1 |
| Hu-Lowe, DD; McDonald, DM; Nakahara, T; Norberg, SM; Shalinsky, DR | 1 |
| Arap, W; Chanthery, YH; Kasman, IM; McDonald, DM; Ozawa, MG; Pasqualini, R; Varner, AS; Yao, VJ | 1 |
| Brooks, P; Davis, R; Freimark, B; Hu-Lowe, DD; Inai, T; Mancuso, MR; McDonald, DM; Nakahara, T; Norberg, SM; O'Brien, S; Sennino, B; Shalinsky, DR; Yao, VJ | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Ishitsuka, K; Kumar, R; Kumar, S; Legouill, S; Pandite, LN; Podar, K; Sattler, M; Tai, YT; Tonon, G; Yasui, H | 1 |
| Brasch, RC; Fleming, LM; Gibbs, J; Henry, RG; Hu-Lowe, D; Hylton, NM; Li, KL; Lu, Y; McShane, TM; Pallavicini, MG; Park, JW; Partridge, SC; Shalinsky, DR; Wang, D; Wilmes, LJ | 1 |
| Bravo, AI; Gazzaniga, S; Guglielmotti, A; Mantovani, A; Maschi, F; Mordoh, J; van Rooijen, N; Vecchi, A; Wainstok, R | 1 |
| Baz, RC; Bukowski, RM; Choueiri, TK; Elson, P; Garcia, JA; Golshayan, AR; Khasawneh, M; Rini, BI; Usman, S; Wood, L | 1 |
| Boloor, A; Cheung, M; Crosby, RM; Crouthamel, MC; Epperly, AH; Gilmer, TM; Harrington, LE; Hopper, TM; Johnson, JH; Knick, VB; Kumar, R; Luttrell, DK; Miller, CG; Mullin, RJ; Onori, JA; Rudolph, SK; Stafford, JA; Truesdale, AT | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Fenton, BM; Paoni, SF | 1 |
13 review(s) available for indazoles and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
The role of pazopanib on tumour angiogenesis and in the management of cancers: A review.
Topics: Angiogenesis Inhibitors; Humans; Indazoles; Neoplasms; Neovascularization, Pathologic; Pyrimidines; Sulfonamides | 2017 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
Linifanib: current status and future potential in cancer therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indazoles; Neoplasms; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors | 2015 |
Pazopanib in ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Disease-Free Survival; Female; Humans; Indazoles; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2015 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Anthracyclines; Biphenyl Compounds; Cardiac Glycosides; Humans; Hypoxia-Inducible Factor 1; Indazoles; Lignans; Models, Biological; Neoplasms; Neovascularization, Pathologic; Retinal Neovascularization; Vascular Endothelial Growth Factors | 2016 |
[Antiangionic drugs in soft tissue sarcoma].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Doxorubicin; Humans; Indazoles; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
In pursuit of new anti-angiogenic therapies for cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2011 |
[Novelties in the treatment for advanced renal-cell cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
9 trial(s) available for indazoles and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cardiotoxicity; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Ovarian Neoplasms; Progression-Free Survival; Pyrimidines; Stilbenes; Sulfonamides; Survival Rate | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Transitional Cell; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neovascularization, Pathologic; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Failure; Urologic Neoplasms; Urothelium | 2013 |
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasms; Neovascularization, Pathologic; Proportional Hazards Models; Protein Stability; Proteolysis; Pyrimidines; Sulfonamides; Texas; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53; Vorinostat; Young Adult | 2015 |
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Indazoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrimidines; Sulfonamides; Treatment Outcome | 2010 |
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
Topics: Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Cytokines; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pyrimidines; Sulfonamides | 2010 |
A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Biomarkers, Tumor; Demography; Disease Progression; Female; Humans; Indazoles; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Statistics, Nonparametric; Time Factors | 2011 |
A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anorexia; Asian People; Carcinoma; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrimidines; Sulfonamides; Treatment Outcome; Vomiting | 2011 |
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Axitinib; Drug Administration Schedule; Drug Interactions; Female; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neovascularization, Pathologic; Treatment Outcome | 2005 |
73 other study(ies) available for indazoles and Angiogenesis, Pathologic
| Article | Year |
|---|---|
AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model.
Topics: Adolescent; Animals; Antibiotics, Antineoplastic; Bone Neoplasms; Disease Models, Animal; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Everolimus; Female; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Osteosarcoma; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; TOR Serine-Threonine Kinases | 2021 |
Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Molecular Docking Simulation; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Thiourea | 2017 |
Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice.
Topics: Animals; Arteries; Atherosclerosis; Axitinib; Cell Adhesion Molecules; Cells, Cultured; Coronary Artery Disease; Disease Models, Animal; Female; Fibrillin-1; Genetic Predisposition to Disease; Hemorrhage; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Indazoles; Mice, Knockout, ApoE; Myocardial Infarction; Neovascularization, Pathologic; Phenotype; Plaque, Atherosclerotic; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Rupture, Spontaneous; Signal Transduction; Ventricular Function, Left | 2018 |
Cyclopropane Modification of Trehalose Dimycolate Drives Granuloma Angiogenesis and Mycobacterial Growth through Vegf Signaling.
Topics: Angiogenesis Inhibitors; Animals; Bacterial Proteins; Cord Factors; Disease Models, Animal; Humans; Indazoles; Macrophages; Methyltransferases; Mycobacterium Infections, Nontuberculous; Mycobacterium marinum; Mycolic Acids; Neovascularization, Pathologic; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sulfonamides; Tuberculoma; Zebrafish | 2018 |
Noninvasive Contrast-Free 3D Evaluation of Tumor Angiogenesis with Ultrasensitive Ultrasound Microvessel Imaging.
Topics: Angiogenesis Inhibitors; Animals; Blood Flow Velocity; Carcinoma, Renal Cell; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Contrast Media; Humans; Image Interpretation, Computer-Assisted; Indazoles; Kidney Neoplasms; Microvessels; Models, Biological; Neovascularization, Pathologic; Phantoms, Imaging; Proof of Concept Study; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib; Ultrasonography | 2019 |
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Line, Tumor; Disease Models, Animal; Humans; Hypoxia; Imidazoles; Indazoles; Male; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-α-induced TGF-α expression and MEK/VEGF-A-mediated angiogenesis.
Topics: Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Down-Regulation; Flavonoids; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Receptor, PAR-2; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor alpha; Up-Regulation; Vascular Endothelial Growth Factor A | 2013 |
Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dacarbazine; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Solitary Fibrous Tumors; Sulfonamides; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2013 |
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Blood Vessels; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides; Sunitinib | 2013 |
Pharmacologic characterization of a kinetic in vitro human co-culture angiogenesis model using clinically relevant compounds.
Topics: Angiogenesis Inhibitors; Axitinib; Biomarkers; Cells, Cultured; Coculture Techniques; Drug Evaluation, Preclinical; Fibroblast Growth Factor 2; Green Fluorescent Proteins; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Indazoles; Inhibitory Concentration 50; Kinetics; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A | 2013 |
Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Proliferation; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2014 |
Vascular-targeted agents for the treatment of angiosarcoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Axitinib; Bevacizumab; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Movement; Doxorubicin; Everolimus; Hemangiosarcoma; Humans; Imidazoles; Indazoles; Neovascularization, Pathologic; Paclitaxel; Protein Array Analysis; Sirolimus; Vascular Endothelial Growth Factor A | 2014 |
Antiangiogenic therapy inhibits venous thrombus resolution.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Animals; Axitinib; Blood Coagulation; Capillary Permeability; Collagen; Estradiol; Imidazoles; Indazoles; Macrophages; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Neutrophils; Thrombophilia; Vena Cava, Inferior; Venous Thrombosis | 2014 |
Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Heterocyclic Compounds, 3-Ring; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Inhibitor of Apoptosis Proteins; Interleukin-8; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction; Sirolimus; Skin Neoplasms; Survivin; Tumor Burden; Vascular Endothelial Growth Factor A | 2014 |
Treatment of collecting duct carcinoma: current status and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides | 2014 |
Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
Topics: Administration, Oral; Antineoplastic Agents; Axitinib; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Imidazoles; Immunohistochemistry; Indazoles; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Axitinib sensitization of high Single Dose Radiotherapy.
Topics: Animals; Apoptosis; Axitinib; Endothelial Cells; Imidazoles; Indazoles; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Protein Kinase Inhibitors; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage; Receptors, Vascular Endothelial Growth Factor; Sarcoma, Experimental; Signal Transduction | 2014 |
Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Axitinib; Brain Neoplasms; Cell Line, Tumor; Female; Glioblastoma; Humans; Imidazoles; Indazoles; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplastic Stem Cells; Neovascularization, Pathologic; Protein Kinase Inhibitors; Random Allocation; Receptors, Vascular Endothelial Growth Factor; Survival Analysis | 2015 |
Topical axitinib suppresses angiogenesis pathways induced by pulsed dye laser.
Topics: Administration, Cutaneous; Angiogenesis Inhibitors; Animals; Axitinib; Combined Modality Therapy; Extracellular Signal-Regulated MAP Kinases; Imidazoles; Indazoles; Lasers, Dye; Male; MAP Kinase Signaling System; Neovascularization, Pathologic; Port-Wine Stain; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Recurrence; Ribosomal Protein S6 Kinases; RNA, Messenger | 2015 |
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1 (HS3ST3B1) promotes angiogenesis and proliferation by induction of VEGF in acute myeloid leukemia cells.
Topics: Axitinib; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Sulfotransferases; Vascular Endothelial Growth Factor A | 2015 |
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Cell Line, Tumor; Chick Embryo; Combined Modality Therapy; Cymenes; Disease Models, Animal; Doxorubicin; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Oxygen Consumption; Photochemotherapy; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tumor Burden | 2015 |
1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Sorafenib; Wnt Signaling Pathway | 2015 |
Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytarabine; Drug Resistance, Neoplasm; Endothelial Cells; Gene Expression Regulation, Leukemic; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sulfonamides; Tumor Burden; Vascular Endothelial Growth Factor A | 2015 |
Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Extracellular Fluid; HT29 Cells; Humans; Imatinib Mesylate; Indazoles; Infusions, Parenteral; Mice; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Peritoneal Absorption; Peritoneum; Pressure; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tumor Burden; Weight Loss; Xenograft Model Antitumor Assays | 2015 |
Spheroid-plug model as a tool to study tumor development, angiogenesis, and heterogeneity in vivo.
Topics: Animals; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Carcinogenesis; Cell Proliferation; Cell Survival; Collagen; Drug Combinations; Endothelial Cells; Hematopoietic Stem Cells; Imidazoles; Indazoles; Injections, Subcutaneous; Laminin; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Neovascularization, Pathologic; Proteoglycans; Receptors, CXCR4; Spheroids, Cellular; Tumor Cells, Cultured | 2016 |
Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases.
Topics: Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Lung Neoplasms; Molecular Docking Simulation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Structure-Activity Relationship; Sulfonamides; Vascular Endothelial Growth Factor A | 2015 |
Murine colitis treated with multitargeted tyrosine kinase inhibitors.
Topics: Animals; Axitinib; Colitis; Imidazoles; Indazoles; Indoles; Male; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Female; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indazoles; Kaplan-Meier Estimate; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Pyrimidines; Real-Time Polymerase Chain Reaction; Sulfonamides; Topotecan; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.
Topics: Adenosine Diphosphate; Animals; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Platelets; Cell Hypoxia; Cell Line, Tumor; Female; Focal Adhesion Kinase 1; Humans; Indazoles; Mice; Mice, Knockout; Neoplasm Proteins; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Female; Genotype; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Immunoglobulin Fc Fragments; Indazoles; Indoles; Kidney Neoplasms; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Renal Cell; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Random Allocation; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Folate-Hapten-Mediated Immunotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer.
Topics: Animals; Antineoplastic Agents; Axitinib; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Female; Folic Acid; Haptens; Humans; Imidazoles; Immunotherapy; Indazoles; Mice; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; T-Lymphocyte Subsets; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Indazoles; Liver Neoplasms; Mice; Mice, SCID; Neovascularization, Pathologic; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinases; Receptor Protein-Tyrosine Kinases; Sirolimus; Subcutaneous Fat; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Blotting, Western; Cell Line, Tumor; Drug Synergism; Female; Humans; Imidazoles; Immunohistochemistry; Immunoprecipitation; Indazoles; Mice; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
Response to antiangiogenesis therapy in a patient with advanced adult-type testicular granulosa cell tumor.
Topics: Adult; Aged; Granulosa Cell Tumor; Humans; Indazoles; Male; Neovascularization, Pathologic; Pyrimidines; Salvage Therapy; Sulfonamides; Testicular Neoplasms; Tomography, X-Ray Computed | 2009 |
Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Disease Models, Animal; Drug Delivery Systems; Imidazoles; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Pleiotropic effects of YC-1 selectively inhibit pathological retinal neovascularization and promote physiological revascularization in a mouse model of oxygen-induced retinopathy.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Indazoles; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Neovascularization, Physiologic; Oxygen; Retinal Diseases; Retinal Neovascularization | 2010 |
The indazole derivative YD-3 specifically inhibits thrombin-induced angiogenesis in vitro and in vivo.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Blotting, Western; Cell Proliferation; Cells, Cultured; Humans; Indazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Thrombin; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biological Therapy; Cell Death; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indazoles; Kaplan-Meier Estimate; Mice; Models, Biological; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cyclophosphamide; Dose-Response Relationship, Drug; Endothelial Cells; Female; Humans; Indazoles; Irinotecan; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Effect of pazopanib on tumor microenvironment and liposome delivery.
Topics: Angiogenesis Inhibitors; Animals; Cell Hypoxia; Doxorubicin; Drug Delivery Systems; Extracellular Fluid; Humans; Indazoles; Liposomes; Mice; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Pressure; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sulfonamides; Tissue Distribution; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.
Topics: Animals; Apoptosis; Axitinib; Blotting, Western; Bone Marrow Neoplasms; Child; Drug Synergism; Endothelium, Vascular; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Neuroblastoma; Phosphorylation; Sirolimus; Stem Cells; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2011 |
Hypoxia-inducible factor-1α is essential for hypoxia-induced mesenchymal stem cell mobilization into the peripheral blood.
Topics: Animals; Blood Cells; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cell Movement; Cells, Cultured; Chemokine CXCL12; Colony-Forming Units Assay; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunophenotyping; Indazoles; Male; Mesenchymal Stem Cells; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A | 2011 |
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Axitinib; Blotting, Western; Camptothecin; Cation Transport Proteins; Cell Proliferation; Cells, Cultured; Copper-Transporting ATPases; Drug Synergism; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunoenzyme Techniques; Indazoles; Irinotecan; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thrombospondins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Antiangiogenesis enhances intratumoral drug retention.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Cyclophosphamide; Drug Synergism; Gliosarcoma; Imidazoles; Indazoles; Male; Mice; Mice, Inbred ICR; Mice, SCID; Neovascularization, Pathologic; Random Allocation; Rats; Receptors, Vascular Endothelial Growth Factor; Transplantation, Heterologous | 2011 |
ABT-869, a multitargeted receptor tyrosine kinase inhibitor, reduces tumor microvascularity and improves vascular wall integrity in preclinical tumor models.
Topics: Animals; Capillary Permeability; Cell Line, Tumor; Drug Evaluation, Preclinical; Endothelium, Vascular; Humans; Indazoles; Mice; Neovascularization, Pathologic; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2011 |
Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
Topics: Administration, Topical; Angiogenesis Inhibitors; Animals; Cell Movement; Choroid; Down-Regulation; Endothelial Cells; Humans; Indazoles; Intracellular Space; Macular Degeneration; Male; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidines; Rats; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sulfonamides; Vascular Endothelial Growth Factor A | 2011 |
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Topics: Administration, Metronomic; Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Endothelial Cells; Humans; Indazoles; Mice; Mice, Inbred NOD; Mice, SCID; Microvessels; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neuroblastoma; Osteosarcoma; Pyrimidines; Random Allocation; Rhabdomyosarcoma; Stem Cells; Sulfonamides; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2011 |
The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indazoles; MAP Kinase Signaling System; Melanoma; Mice; Neovascularization, Pathologic; Proto-Oncogene Proteins B-raf; Pyrimidines; Sulfonamides; Xenograft Model Antitumor Assays | 2011 |
Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo.
Topics: Animals; Doxorubicin; Drug Delivery Systems; Female; Humans; Hypoxia; Immunoenzyme Techniques; Indazoles; Mammary Neoplasms, Animal; Mice; Mice, Nude; Mice, Transgenic; Microvessels; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Sulfonamides | 2012 |
A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model.
Topics: Animals; Brain Neoplasms; Cell Growth Processes; Disease Models, Animal; Female; Glioma; Immunohistochemistry; Indazoles; Magnetic Resonance Angiography; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Inbred F344; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2012 |
Insufficient radiofrequency ablation promotes angiogenesis of residual hepatocellular carcinoma via HIF-1α/VEGFA.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Hepatocellular; Catheter Ablation; Cell Survival; Culture Media, Conditioned; Hep G2 Cells; Hot Temperature; Humans; Hyperthermia, Induced; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Liver Neoplasms; Mice; Neovascularization, Pathologic; RNA, Small Interfering; Signal Transduction; Treatment Failure; Vascular Endothelial Growth Factor A | 2012 |
Antiangiogenic role of miR-361 in human umbilical vein endothelial cells: functional interaction with the peptide somatostatin.
Topics: Algorithms; Angiogenesis Inhibitors; Blotting, Western; Cell Hypoxia; Cell Proliferation; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1; Indazoles; MicroRNAs; Neovascularization, Pathologic; Polymerase Chain Reaction; Signal Transduction; Somatostatin; STAT3 Transcription Factor; Vascular Endothelial Growth Factor A | 2013 |
Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.
Topics: Angiogenesis Inhibitors; Animals; Anthraquinones; Antineoplastic Agents; Axitinib; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Hydralazine; Imidazoles; Indazoles; Male; Mice; Mice, Nude; Mice, SCID; NAD(P)H Dehydrogenase (Quinone); Neoplasms; Neovascularization, Pathologic; Rats; Regional Blood Flow; Vasodilator Agents; Xenograft Model Antitumor Assays | 2013 |
Is HIF-1 alpha a valid therapeutic target?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Disease Models, Animal; Endothelial Growth Factors; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Neoplasms; Neovascularization, Pathologic; Repressor Proteins; Trans-Activators; Transcription Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Hepatocellular; Cell Hypoxia; Culture Media, Conditioned; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Female; G(M1) Ganglioside; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Indazoles; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lymphokines; Male; Mice; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Neuroblastoma; Platelet Endothelial Cell Adhesion Molecule-1; Precipitin Tests; Rats; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Transcription Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Blotting, Western; Cell Movement; Cell Proliferation; Endothelial Cells; Endothelium, Vascular; Enzyme Activators; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Guanylate Cyclase; Humans; Indazoles; Longevity; Microtubules; Neoplasms; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Protein Kinase C; Signal Transduction; Tetrazolium Salts; Thiazoles; Thymidine; Vascular Endothelial Growth Factor A | 2005 |
Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development?
Topics: Administration, Oral; Angiogenesis Inhibitors; Axitinib; Biomarkers, Tumor; Clinical Trials as Topic; Diagnostic Imaging; Drug Design; Drugs, Investigational; Humans; Imidazoles; Indazoles; Neoplasms; Neovascularization, Pathologic | 2005 |
New drugs target hypoxia response in tumors.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; DNA-Binding Proteins; Drugs, Investigational; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mustard Compounds; Neoplasms; Neovascularization, Pathologic; Nuclear Proteins; Phenylpropionates; Topotecan; Transcription Factors; Transplantation, Heterologous | 2005 |
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
Topics: Animals; Axitinib; Breast Neoplasms; Female; Humans; Image Enhancement; Imidazoles; Indazoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Transplantation, Heterologous | 2005 |
YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits neointima formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metalloproteinases 2 and 9.
Topics: Angiogenesis Inhibitors; Animals; Carotid Arteries; Catheterization; Cyclic GMP; Enzyme-Linked Immunosorbent Assay; Fluorescent Dyes; Immunohistochemistry; Indazoles; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neovascularization, Pathologic; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Colonic Neoplasms; Erythrocyte Volume; Humans; Indazoles; Magnetic Resonance Angiography; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Radionuclide Imaging; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2005 |
Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors.
Topics: Adenoma, Islet Cell; Animals; Antibodies, Neoplasm; Axitinib; Cadherins; Carcinoma, Lewis Lung; Fibrin; Imidazoles; Immunoglobulin G; Indazoles; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microspheres; Neovascularization, Pathologic; Signal Transduction; Vascular Endothelial Growth Factor A | 2006 |
Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels.
Topics: Adenoma, Islet Cell; Animals; Axitinib; Bacteriophage M13; Endothelial Cells; Female; Imidazoles; Indazoles; Integrin alpha5beta1; Integrin alphaVbeta3; Male; Mice; Mice, Transgenic; Microscopy, Fluorescence; Neovascularization, Pathologic; Oligopeptides; Pancreatic Neoplasms; Substrate Specificity | 2006 |
Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
Topics: Actins; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Axitinib; Basement Membrane; Blood Vessels; Carcinoma, Lewis Lung; Collagen Type IV; Endothelium, Vascular; Imidazoles; Indazoles; Insulinoma; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms; Neovascularization, Pathologic; Organic Chemicals; Pericytes; Platelet Endothelial Cell Adhesion Molecule-1; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Movement; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Immunoprecipitation; Indazoles; Mice; Microarray Analysis; Multiple Myeloma; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Sulfonamides | 2006 |
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Axitinib; Breast Neoplasms; Capillary Permeability; Cell Proliferation; Contrast Media; Female; Imidazoles; Indazoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Receptors, Vascular Endothelial Growth Factor; src-Family Kinases; Treatment Outcome | 2007 |
Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft.
Topics: Animals; Cell Line, Tumor; Chemokine CCL2; Clodronic Acid; Humans; Indazoles; Liposomes; Macrophages; Male; Melanoma, Experimental; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Transplantation, Heterologous | 2007 |
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2007 |
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell-Free System; Cornea; Dose-Response Relationship, Drug; Female; Fibroblast Growth Factor 2; Humans; Indazoles; Inhibitory Concentration 50; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Sulfones; Vascular Endothelial Growth Factor A | 2007 |
The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.
Topics: Actins; Angiogenesis Inhibitors; Animals; Apoptosis; Axitinib; Cell Growth Processes; Cell Hypoxia; Collagen Type IV; Combined Modality Therapy; Dose Fractionation, Radiation; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prostatic Neoplasms; Receptor, Platelet-Derived Growth Factor beta; Xenograft Model Antitumor Assays | 2007 |